Echinacea

Echinacea purpurea (L.) Moench sits in Asteraceae. NCBI Taxonomy treats it as taxon 53751. Linnaeus named it Rudbeckia purpurea in Species Plantarum (1753); Moench moved it to Echinacea in 1794. IPNI records that combination as 1174497-2. It is a perennial of mesic prairies and open woods east of the Rockies, now a garden staple worldwide: coarse lance-ovate leaves, unbranched or sparingly branched stems, and the hedgehog flower head that gives the genus its name (echinos, hedgehog). The medicinal aerial drug is flowering herb; the root is a separate pharmacopeial object.

E. angustifolia DC. (NCBI 308558) is the narrow-leaved purple coneflower of drier Great Plains ground. E. pallida (Nutt.) Nutt. is pale coneflower, with longer, paler, more strongly drooping rays. EMA files the dried roots of all three as distinct herbal substances. Before 1968, angustifolia and pallida were often treated as varieties of one species; they are not interchangeable extracts. Other Echinacea species (paradoxa, tennesseensis, laevigata) are conservation or ornamental stories, not the cold-trial material.

Do not confuse the genus with Rudbeckia hirta (black-eyed Susan), whose disk is softer and whose rays do not droop the same way. Do not treat “coneflower tea from the border” as Echinacin. Cultivated E. purpurea is the usual commercial aerial crop. Wild-dug angustifolia root has a conservation and adulteration history.

Chemistry splits by species and organ. Caffeic acid derivatives: cichoric acid (PubChem CID 5281764) is the usual marker in E. purpurea herb and root; echinacoside (CID 5281771) is the major caffeoyl glycoside of E. angustifolia and E. pallida roots and is typically low or absent in purpurea root. Alkylamides (isobutylamides) tingle the tongue; they bind CB2 in experimental systems and are the sensory quality check for some tinctures. Polysaccharides and glycoproteins were the 1980s immune-stimulant story. Volatile polyenes sit in pallida root. Gilroy and colleagues (Archives of Internal Medicine 2003) found US products that did not contain the labeled species. Two bottles can share a hedgehog on the label and not share an alkylamide.

Plains Nations used Echinacea roots for toothache, sore throat, wounds, and snakebite long before a German juice plant existed. The Eclectic physicians of the nineteenth-century United States made E. angustifolia root a professional anti-infective and “alterative.” That is a medical-culture history, not a rhinovirus RCT. The plant crossed to Europe as an ornamental and then as a phytomedicine. Madaus and later German manufacturers built Echinacin-style expressed juices from fresh E. purpurea herb—the product class EMA still treats as well-established.

Late-twentieth-century North America turned the same genus into the default cold supplement. Goldenseal-echinacea blends, zinc lozenges, and “immune” teas piled on. Quality lagged: Gilroy 2003 is the labeling paper people still cite. Cochrane reviews (Melchart, then Linde, then Karsch-Völk 2014) tried to make one answer out of many extracts and mostly could not. Shah’s 2007 Lancet Infectious Diseases meta-analysis was more optimistic on prevention; Cochrane 2014 was more cautious and more honest about heterogeneity. NCCIH’s consumer page sits between them: a possible small prevention effect, unclear shortening of illness.

EMA adopted a well-established-use monograph for fresh E. purpurea herb juice (revision 24 November 2014, corrected 2015) and a separate traditional-use file for E. purpurea root (revision 2017: cold symptoms or mild acne). Angustifolia and pallida roots have their own traditional monographs. That regulatory split is the history: juice of one species’ aerial parts got the higher evidence rank; roots stayed traditional. In the United States the same plants are dietary supplements. History here is a product-class file, not a single prairie flower.

EMA is blunt on the well-established juice: the mechanism of action is not known. Marketing is not. Alkylamides can bind cannabinoid CB2 receptors and damp TNF-α in cell work. Cichoric acid is an antioxidant caffeoyl tartaric ester in dishes. Polysaccharides activate macrophages in older assays. Haron, Tyler, Pugh and colleagues (Planta Medica 2016), in NCCIH-supported work, found that Proteobacteria living in E. purpurea fully accounted for the macrophage activation of some extracts—bacterial LPS as a confounder of “immune stimulation.” That paper is a methods warning: two lots of prairie flower are not one drug.

Immunostimulation is why autoimmune disease and transplant drugs show up in cautions. It is also why year-round use was never the EMA plan. A ten-day cold course is not a chronic cytokine protocol. Effects on CYP1A2 and CYP3A4 appear in vitro and in some human phenotyping; clinical importance is unsettled (MSKCC, LiverTox). Etoposide thrombocytopenia is a case-level CYP3A4 worry. Immunosuppressants are a theoretical antagonism. Tongue tingle from a tincture is alkylamides, not proof the cold will be shorter.

The common cold is the indication that emptied the shelves. NCCIH: taking echinacea may slightly reduce your chances of catching a cold; whether it shortens a cold is unclear. Cochrane 2014: 24 double-blind trials, 33 comparisons, products too heterogeneous to pool as one medicine; no single prevention trial of “at least one cold” was statistically significant; a post-hoc pool suggested a 10–20% relative risk reduction of questionable clinical size; of seven treatment trials reporting duration, only one was significant. David and Cunningham (Complementary Therapies in Medicine 2019) meta-analyzed upper-respiratory trials and still had to live with product scatter. Shah 2007 was the more positive prevention meta Cochrane later complicated. Read the stack, not the aisle sign.

Negative landmarks matter. Turner, Bauer, Woelkart, Hulsey, and Gangemi (NEJM 2005) experimentally infected volunteers with rhinovirus and tested three E. angustifolia root extracts (supercritical CO2, 60% ethanol, 20% ethanol) as prophylaxis and treatment: no significant effect on infection rate or symptom severity. Barrett, Brown, Rakel and colleagues (Ann Intern Med 2010) randomized Wisconsin adults with new colds to no pill, placebo, or echinacea (root and herb of E. purpurea and E. angustifolia) and found no statistically significant duration benefit, with a possible half-day trend that was not clinically decisive. Taylor, Weber, Standish et al. (JAMA 2003) found E. purpurea not effective for upper-respiratory infections in children and saw more rash. Those are not “the wrong brand” footnotes. They are why mixed reviews stay mixed.

EMA well-established use is narrower: oral expressed juice (or dried juice equivalent) of fresh E. purpurea herb, start at first signs, adolescents and adults, maximum ten days, see a doctor or pharmacist if symptoms last longer. Traditional root products: cold-symptom relief (and, for purpurea root, mild acne) on long-standing use. Topical herb juice: traditional small superficial wounds. An Echinacea hot drink compared with oseltamivir in one influenza non-inferiority trial (Raus 2015, in the MSKCC stack) is a formulated combination product, not a license to skip indicated antivirals.

Year-round “immune boosting,” cancer prevention, HIV, and chronic fatigue are marketing. Preclinical cytokine and NK-cell stories are not a supplement protocol. Do not treat influenza, strep, COVID-19, or a child’s fever with a prairie flower as the only plan. Goldenseal-echinacea-zinc blends are a mixture, not stronger proof.

EMA well-established oral products: expressed juice of fresh E. purpurea flowering herb, DER 1.5–2.5:1, 1.5–4.5 ml per dose, 6–9 ml per day (or dried juice equivalent). Start at the first signs of a cold. Do not use more than ten days. Not for children under twelve. That is the juice file, not a tea bag of dried petals.

Traditional root products: dried E. purpurea, E. angustifolia, or E. pallida root as extracts, tinctures, or oromucosal forms on labeled traditional posology. EMA root indications are cold-symptom relief (and mild acne for some purpurea-root extracts), not the well-established juice claim. Topical herb preparations: small superficial wounds, up to one week; infection needs a clinician.

US supplements: dried herb, dried root, hydroalcoholic tinctures, capsules, gummies, and blends with goldenseal, elderberry, vitamin C, and zinc. Species and plant part are often missing. Gilroy 2003 found mislabeled products. Look for Echinacea purpurea herb juice if you want the EMA object; look for a named root if you want the Eclectic object. They are not bioequivalent. The tongue-tingle of alkylamides is a crude identity check for some tinctures, not a dose.

Do not graze garden coneflowers as a cold protocol. Do not give medicinal extracts to children as a winter plan; Taylor 2003 is the pediatric caution, and EMA does not recommend under twelve. A cold lasting more than ten days, high fever, or chest symptoms is not a second bottle.

Common: digestive-tract symptoms—abdominal pain, nausea, stomach pain (NCCIH). Headache, dizziness, constipation, and rash also appear (MSKCC). Prevention trials in Cochrane’s pool trended toward more dropouts for adverse events in echinacea arms.

Allergy: urticaria, facial swelling, asthma, angioedema, Stevens-Johnson syndrome, and anaphylactic shock are reported, especially in atopic people (EMA). Frequency unknown. People who react to ragweed, chrysanthemums, marigolds, or chamomile are the obvious risk group. Taylor 2003 linked echinacea with more rash in children.

Liver: LiverTox likelihood D—possible rare cause of clinically apparent injury. Isolated jaundice cases one to three weeks in, usually recovering on stopping; some national-registry hepatitis reports. Mechanism unclear; contaminant and hypersensitivity are both nominated. Jaundice still means stop and get labs. This is not kava’s or ashwagandha’s denser file.

Other case-level signals in MSKCC: leukopenia with chronic use, autoimmune pemphigus flare, TTP, hypereosinophilia, etoposide-associated thrombocytopenia. Chronic daily “immune” capsules are how those stories start. EMA’s ten-day cap exists for a reason.

Do not use if you are allergic to echinacea or other Asteraceae. EMA: not recommended in progressive systemic disorders, autoimmune diseases, immunodeficiencies, immunosuppression, and diseases of the white-blood-cell system. Atopic patients should speak with a doctor first because severe hypersensitivity is the known risk.

Not for children under twelve as a well-established or traditional EMA product. Taylor’s pediatric RCT did not show benefit and saw more rash. High fever or a sick infant is emergency care, not a tincture.

Pregnancy and lactation: EMA has limited observational data without a clear harm signal and still does not recommend use unless a doctor advises it. MSKCC: talk with a clinician; safety is not established. Do not apply topical echinacea to the breast while nursing.

A cold is still a cold. Echinacea is not oseltamivir, not an antibiotic, and not a reason to skip vaccination. People on transplant immunosuppressants or some chemotherapy (etoposide, possibly other CYP3A4 substrates) need the oncology or transplant team, not a prairie protocol.

EMA’s well-established juice monograph lists no reported drug interactions. That is a regulatory sentence for that specific preparation, not a blank check for every tincture.

Immunosuppressants (cyclosporine, tacrolimus, and kin): theoretical antagonism because of immunostimulant folklore and an autoimmune-flare case (Lee and Werth 2004). MSKCC flags this. If you take anti-rejection drugs, skip the cold herb.

CYP: in-vitro and some in-vivo signals for CYP1A2 and CYP3A4; CYP2C8 and P-gp in dishes. Docetaxel pharmacokinetics did not clearly change in one cancer-patient study. Etoposide thrombocytopenia is the case that still sits in reviews. Caffeine (CYP1A2) is a theoretical footnote. Tell a pharmacist.

Do not stack echinacea, goldenseal, elderberry, zinc, and vitamin C and then credit one plant when the cold lasts five days either way. Blends erase the trial that never quite applied.